HIV/AIDS Treatment

Support program helps physicians, patients overcome injection-related barriers

Published in Health and Medicine Week, August 2nd, 2004

An enfuvirtide (Fuzeon) support program developed at the North Jersey Community Research Initiative (NJCRI) is showing remarkable success in helping physicians and patients to overcome injection-related barriers, according to new research presented at the XV International AIDS Conference (IAC) in Thailand.

Enfuvirtide is the first approved fusion inhibitor for the treatment of HIV infection. It works by blocking HIV from entering the human immune (CD4) cell.

Enfuvirtide is also unique in that it is self-administered as an injection, a route that prevents some treatment-experienced patients from considering it as an option, even when the introduction...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health and Medicine Week

Source: Health and Medicine Week (2004-08-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry